Similar articles

• The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer.

  Schneider U, Lomax A, Besserer J, Pemler P, Lombriser N, Kaser-Hotz B. Schneider U, et al. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):892-7. doi: 10.1016/j.ijrobp.2007.02.029. Epub 2007 Apr 24. Int J Radiat Oncol Biol Phys. 2007. PMID: 17459608
• Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy.

  Al-Salihi O, Mitra A, Payne H. Al-Salihi O, et al. Prostate Cancer Prostatic Dis. 2006;9(4):370-3. doi: 10.1038/sj.pcan.4500893. Epub 2006 Jul 11. Prostate Cancer Prostatic Dis. 2006. PMID: 16832383 Review.
• Is there a limit to dose escalation for rectal cancer?

  Cummings BJ. Cummings BJ. Clin Oncol (R Coll Radiol). 2007 Nov;19(9):730-7. doi: 10.1016/j.clon.2007.07.007. Epub 2007 Sep 17. Clin Oncol (R Coll Radiol). 2007. PMID: 17869492 Review.
• Dose escalation for prostate cancer using the three-dimensional conformal dynamic arc technique: analysis of 542 consecutive patients.

  Jereczek-Fossa BA, Vavassori A, Fodor C, Santoro L, Zerini D, Cattani F, Garibaldi C, Cambria R, Fodor A, Boboc GI, Vitolo V, Ivaldi GB, Musi G, de Cobelli O, Orecchia R. Jereczek-Fossa BA, et al. Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):784-94. doi: 10.1016/j.ijrobp.2007.10.041. Epub 2008 Jan 11. Int J Radiat Oncol Biol Phys. 2008. PMID: 18191332 Clinical Trial.
• Exploring dose-intensity: carefully comparing high-dose with low-dose external-beam radiotherapy for prostate cancer.

  Sandler HM. Sandler HM. J Clin Oncol. 2006 May 1;24(13):1975-7. doi: 10.1200/JCO.2006.05.7612. J Clin Oncol. 2006. PMID: 16648496 No abstract available.